Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Heilongjiang Yida Hong Pharmaceutical is a Chinese pharmaceutical company established in 2021 and based in Hulin City, Heilongjiang Province. The company focuses on the development and manufacturing of chemical drug preparations, particularly in the cardiovascular therapeutic area. Its pipeline includes HKGM-453, a small molecule candidate currently in Phase 1 clinical trials for essential hypertension, and Nicorandil tablets, which are marketed for the treatment of angina pectoris. The company operates a modern manufacturing facility with production lines for tablets, including granulation, compression, and coating capabilities. In 2024, the company reported significant production volumes, completing over three million boxes of pharmaceutical products to meet market demand.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Heilongjiang Yida Hong Pharmaceutical.